Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:
Therapeutic Strategies
 
Drug Monitoring                         Stopping NVP Therapies             
Tolerance Induction                   Adherence and Dosing 
Cryptococcal Prophylaxis           IDUs   
Lipodystrophy Prevention          HIV/TB Coinfection
HIV Pre-exposure Prophylaxis
Coronary Risk
 CNS Benefits
 Undetectable Viral Load
 Switching Therapies
Simplification Therapy
 Salvage Therapy   
NVP Main Page  Journal Main Page New/Newsworthy Home Page
Last Update:  December 11, 2008
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Drug Monitoring
 
 
A WEEK IN REVIEW FEATURED REPORT
 Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical
Pharmacokinetic Monitoring?
 Dahri K, Ensom MH. 
Clin Pharmacokinet. 2007;46(2):109-32.
 Abstract

Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
 Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5
 Abstract
Tolerance Induction
           
  Long-term safety and efficacy of nevirapine tolerance induction.
 Messaad D, Reynes J, Fabre J, et al.
Clin Exp Allergy. 2002 May;32(5):733-735.
 Abstract		  
NVP-Based HAART and Fluconazole Cryptococcal
Prophylaxis
  FULL-TEXT PDF ARTICLE
 Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients
receiving fluconazole for cryptococcal prophylaxis: a case-control study
 Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S 
BMC Infectious Diseases 2005, 5:67
Paper		  
Lipodystrophy Prevention
           
  Switching to nevirapine decreases insulin levels but does not improve subcutaneous a
dipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
Domingo P, Matias-Guiu X, Pujol RM, et al.
J Infect Dis 2001 Nov 1;184(9):1197-201
 Abstract 		 
Coronary Risk
           
  A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus
in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized
controlled study.
 Fisac C, Virgili N, Ferrer E, et al  J
Clin Endocrinol Metab. 2003 Nov;88(11):5186-92
 Abstract
Central Nervous System Benefits
           
  Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous
system in HIV-1-infected patients.
 von Giesen HJ, Koller H, Theisen A, Arendt G.
 J Acquir Immune Defic Syndr 2002 Apr 1;29(4):363-7
 Abstract		  
Undetectable Viral Load
 		  
  Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV
-Infected Patients with Undetectable Virus Load.
 Gil P, de Gorgolas M, Estrada V 
Clin Infect Dis. 2004 Oct 1;39(7):1024-9
 Abstract		  
Simplification Therapy
 
  Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
Salvage Therapy
           
  Nelfinavir plus nevirapine plus two nrtis as salvage therapy for hiv-infected patients receiving
antiretroviral treatment.
Perez-Molina JA, Perez Nr R, et al  
HIV Clin Trials 2001 Jan-Feb;2(1):1-5
Abstract
 
Efficacy of a nelfinavir- and nevirapine-containing salvage regimen.
Sullivan AK, Nelson MR, Shaw A, et al
HIV Clin Trials 2000 Jul-Aug;1(1):7-12
 Abstract
 
Stopping NVP-Based Therapy
           
 
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic
resistance after treatment interruption.
 Darwich L, Esteve A, Ruiz L, et al
Antivir Ther. 2008;13(7):945-51.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected
population of a large clinical cohort.
 Maggiolo F, Arici C, Airoldi M,  et al 
J Antimicrob Chemother. 2007 Jan 25;
 Abstract

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative
pharmacokinetics and avoidance of drug resistance.
 Mackie N, Fidler S, Tamm N, et al 
HIV Med. 2004 May;5(3):180-184
 Abstract

Adherence and Dosing
 
  Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized
controlled study.
 Parienti JJ, Massari V, Reliquet V, et  a
AIDS. 2007 Oct;21(16):2217-2222.
 Abstract
 Abstract
HIV Pre-exposure Prophylaxis
 
  A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission
in uninfected subjects at high risk.
 Jackson JB, Barnett S, Piwowar-Manning E, et al.
AIDS 2003 Mar 7;17(4):547-53
 Abstract
HIV/TB Coinfection
           
 
A WEEK-IN-REVIEW FEATURED REPORT
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-
based antiretroviral therapy in HIV-infected patients with tuberculosis.
Manosuthi W, Ruxrungtham K, Likanonsakul S, et al
 Clin Infect Dis. 2007 Jan 1;44(1):141-4.
 Abstract

Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin
Coadministration.
 Ramachandran G, Hemanthkumar AK, Rajasekaran S,  
Acquir Immune Defic Syndr. 2006 Apr 24;
Abstract

NVP Main Page Journal Main Page New/Newsworthy Home Page

Nevirapine Journal Data
Therapeutic Strategies